AbbVie is investing $380 million to expand its US manufacturing capabilities, focusing on neuroscience and obesity medicines, and integrating advanced technologies including artificial intelligence for future pipeline medicines.
On February 23, 2026, AbbVie announced a significant investment of $380 million to build two new active pharmaceutical ingredient (API) manufacturing facilities at its Illinois campus. This move is part of the company’s broader effort to scale up domestic manufacturing, particularly in response to the US government’s tariffs on pharmaceutical imports.
The investment in the new facilities, which are expected to be fully operational by 2029, underscores AbbVie‘s commitment to enhancing its US-based production capacity. The company plans to hire approximately 300 people, including engineers, scientists, manufacturing operators, and lab technicians, to support the expanded operations in North Chicago.
This development is also aligned with AbbVie‘s earlier commitment of $100 billion over the next decade for US-based research and development. The company is further discussing potential projects with multiple US states, indicating a strategic push towards bolstering its domestic footprint in the pharmaceutical sector.
As reported by Reuters, the expansion is set to integrate advanced manufacturing technologies and artificial intelligence, aiming to support the production of future pipeline medicines. This integration highlights the company’s focus on innovation and efficiency in its manufacturing processes.
The decision to invest in US manufacturing comes amidst a broader industry trend of shoring up domestic production capacities. The move is seen as a strategic response to the complexities and challenges associated with global supply chains, especially in the context of pharmaceuticals.
For readers looking to stay updated on the latest developments in the pharmaceutical industry, including investments, innovations, and regulatory changes, onlytrustedinfo.com provides comprehensive and authoritative analysis. Our platform offers the fastest and most insightful coverage of breaking news, ensuring that our audience is always informed about the issues that matter most.
